Full text is available at the source.
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP
Changes in spinal fluid and blood markers across Alzheimer's stages using NF-L, p-tau181, and GFAP levels
AI simplified
Abstract
A total of 173 individuals were evaluated for Alzheimer’s disease biomarkers in both cerebrospinal fluid (CSF) and plasma samples.
- Significant correlations were found between CSF and plasma levels of Aβ42/40, p-tau181, p-tau231, NF-L, and GFAP.
- No correlation was observed between CSF and plasma levels of t-tau and UCHL-1.
- CSF p-tau231 and SNAP-25, along with plasma Aβ42/40, p-tau231, and GFAP, best discriminated between controls and preclinical Alzheimer's disease.
- Aβ42/Aβ40, GFAP, and p-tau231 in plasma demonstrated the largest rate of change at cut-offs defined by CSF biomarkers for amyloidosis and tauopathy.
- GFAP, NF-L, and p-tau181 were most significantly associated with disease progression in both CSF and plasma.
AI simplified